Whalesbook
Navigating Market Turbulence and Midcap Prospects
Indian equity markets are experiencing a challenging phase characterized by persistent foreign institutional investor (FII) outflows and broader global economic uncertainties. The Indian rupee has also faced pressure, contributing to cautious investor sentiment. Despite these headwinds, domestic institutional investors (DIIs) continue to provide a stabilizing influence. This period of market correction has led to improved valuations in the midcap segment, presenting potentially attractive entry points for patient, long-term investors. Analysts suggest that the current market conditions are enhancing the risk-reward profile for quality midcap stocks. The Indian economy is projected for robust growth, with estimates between 7.5% and 7.8% for fiscal year 2025-26, and the nation is on track to become the world's third-largest economy.
Jewellery Sector Shines Amidst Festive Demand
The organized jewellery sector in India demonstrated considerable strength in the third quarter of fiscal year 2026 (ending December 31, 2025). This performance was driven by robust festive season sales and sustained demand from wedding purchases, underscoring the sector's resilience even amidst gold price volatility. Leading players in the organized segment reported significant year-on-year growth, highlighting successful brand strategies and expansion initiatives.
Sky Gold and Diamonds: A B2B Jewellery Manufacturer
Sky Gold and Diamonds Limited, a B2B designer, manufacturer, and marketer of gold jewellery, operates on an asset-light outsourcing model, supplying to organised retailers and boutique stores. As of January 22, 2026, the company's stock was trading at ₹320, with a market capitalization of approximately ₹4,950 crore. It has a Price-to-Earnings (P/E) ratio of 26.7, a book value of ₹66.9, a Return on Capital Employed (ROCE) of 21.2%, and a Return on Equity (ROE) of 25.5%. The company possesses a production capacity of 750-800 kg of gold per month at its Navi Mumbai facility.
Dr. Reddy's Laboratories: International Business Drives Q3 Growth
Dr. Reddy's Laboratories reported its consolidated financial results for the quarter ended December 31, 2024 (Q3 FY25), with revenues increasing by 16% year-on-year to ₹8,358.6 crore. Profit After Tax (PAT) saw a 2% year-on-year rise, reaching ₹1,413.3 crore. The company's stock traded at ₹1,157.20 on January 22, 2026, with a market capitalization of approximately ₹96,583.42 crore and a P/E ratio of 17.34. Dr. Reddy's performance was supported by its expanding international business mix and strategic investments, including progress in new product launches like Semaglutide. The pharmaceutical sector, in general, benefits from a weaker rupee which enhances export competitiveness.
Policy Support for Exporters and Evolving PLI Schemes
The Indian government continues to focus on supporting exporters, with an ambitious target of $850 billion in exports for fiscal year 2026. Production-Linked Incentive (PLI) schemes are evolving, with some nearing their sunset clauses, potentially paving the way for new policy measures aimed at boosting export-oriented businesses and import substitution. Additionally, export benefits, including Duty Drawback and RoDTEP, have been extended to the postal channel, simplifying access for MSMEs and small exporters.